Understanding the role of indoleamine-2,3-dioxygenase and stromal differentiation in rare subtype endometrial cancer

• Published in: Rare tumors Vol. 13; p. 20363613211044690
• Main Authors: Wu, Dongling, Hacking, Sean, Cao, Jin, Nasim, Mansoor
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.09.2021; Sage Publications Ltd; SAGE Publishing
• Subjects: Apoptosis; Carcinoma; Dioxygenase; Endometrial cancer; Endometrium; Immunotherapy; Lymph nodes; Medical prognosis; Metastases; Myometrium; Original; PD-L1 protein; Stroma; Tumors; Uterine cancer; rare subtype endometrial cancer; stromal differentiation; Indoleamine 2,3 dioxygenase
• ISSN: 2036-3613; 2036-3605; 2036-3613
• DOI: 10.1177/20363613211044690

Endometrial cancer (EC) is a disease with good and poor prognostic subtypes. Dedifferentiated endometrial carcinoma (DEC), undifferentiated endometrial carcinoma (UEC), and clear cell endometrial carcinoma (CEC) are rare high-grade tumors, associated with a poor prognosis and high pathologic stage. Many studies have been performed on the programmed death-ligand 1 (PD-L1) axis mainly focus on endometrioid adenocarcinomas and little research has been done on rare subtypes. The present body of work aims to evaluate the role of indoleamine-2,3-dioxygenase (IDO-1) and stromal differentiation (SD), their correlation with clinicopathologic features and overall survival. Here we found that positive IDO-1 expression in immune cells correlated with worse disease-free survival (p = 0.02), recurrence (p = 0.03), high pathologic tumor stage (p = 0.024), lymph node metastasis (p = 0.028), and myometrial invasion (p = 0.03). Our findings suggest IDO-1 to be relevant in both MMR intact and deficient tumors; however, >20% immune cell staining was restricted to MMR deficient cancers. For the stroma, immature, myxoid differentiation was found to correlate with worse disease-free survival (p = 0.04). We also found the correlation between IDO-1 expression and immature stroma. Looking forward, IDO-1 could be promising for immunotherapy and SD could be the answer to clinical heterogeneity.